PT-141

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist, developed by Palatin Technologies. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Mechanism

• Melanocortin 4 receptor (MC4R) agonism. Central mechanism affecting sexual arousal pathways.

Common research protocols

Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.

• FDA-approved dosing (Vyleesi). 1.75 mg subcutaneous, on-demand, at least 45 minutes before anticipated activity, up to 1 dose per 24 hours and 8 doses per month.

Evidence at a glance

• Regulatory. FDA-approved 2019.
• Known side effects. Nausea (common), flushing, injection-site reactions, transient blood pressure elevation.

Reconstitution & handling

Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How It Works page.

Primary-literature list for this guide available on request via contact.